Fortis Therapeutics, Inc.

Expectations were not high for the latest trial of FibroGen, Inc. ’s pamrevlumab in Duchenne muscular dystrophy (DMD); nevertheless, the connective tissue growth factor-targeted product has still con

It was a second clinical trial disappointment in as many months for FibroGen, Inc. as the San Francisco-based firm revealed on 7 June that its CTGF-targeted antibody pamrevlumab missed the primary e

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Gilead Takes On XinThera’s Preclinical

Biopharmaceutical companies raised $1.5bn in 11 venture capital mega-rounds of $100m or more during the last week and a half of March. Including VC and other financings under $100m, 35 privately held